Market Dynamics The global market for treating calciphylaxis exhibited substantial strength in 2021 and is projected to experience a swift Compound Annual Growth Rate (CAGR) in revenue throughout the forecast period. The increasing prevalence of cardiovascular calcification in patients with end-stage renal disease is a key driver behind the growth in revenue for the calciphylaxis treatment market.

Calciphylaxis, an uncommon, painful, and often fatal condition, primarily affects individuals with moderate to severe kidney impairment. This condition leads to the accumulation of calcium deposits in the blood vessels, resulting in blockages and subsequent deterioration and death of surrounding skin and tissue. In rare cases, these deposits can develop internally in organs such as the eyes, lungs, brain, muscles, and intestines. Patients suffering from calciphylaxis require specialized care, including wound management. The presence of calciphylaxis is often associated with hyperparathyroidism.

Calciphylaxis can lead to the formation of blood clots and severe skin ulcers, potentially resulting in life-threatening infections. It most commonly occurs in individuals with kidney failure who are undergoing dialysis or have received a kidney transplant. Symptoms of calciphylaxis include pain, lesions, ulcers, calcification of the heart and major blood vessels, vision problems, internal bleeding, and muscle damage.

Get a sample copy of the Calciphylaxis Treatment Market report: https://www.reportsanddata.com/download-free-sample/5873

Factors Contributing to Market Growth Drivers: A primary driver of calciphylaxis is hyperparathyroidism, which is linked to the dysregulation of calcium and phosphorous metabolism. Treatment involves a multidisciplinary approach encompassing nephrology, dermatopathology, dermatology, pain management, and nutrition. The rising prevalence of kidney diseases and end-stage renal conditions also fuels the demand for advanced calciphylaxis treatments, aiming to reduce hospitalizations and morbidity.

As of November 2020, the International Society of Nephrology reported a global Chronic Kidney Disease prevalence of 10.4% in males and 11.8% in females. Acute kidney injury, affecting 13.3 million people annually, can progress to chronic kidney disease or kidney failure, leading to increased healthcare expenditures for chronic renal disease treatment. These are pivotal factors propelling further revenue growth in the calciphylaxis treatment market during the forecast period.

Challenges: A major challenge for the global calciphylaxis treatment market is the absence of effective treatment options. This lack of a proven treatment approach negatively impacts market revenue growth. Additionally, the high cost of treatments poses a barrier to accessibility for the majority of the population, potentially affecting revenue growth during the forecast period.

Opportunities: Rapidly increasing clinical studies offer significant potential for boosting market revenue growth in the future. Collaborations between companies and research institutes are expanding, promoting clinical studies in various locations. For example, in June 2020, Chinook Therapeutics and Aduro Biotech, both investigating different approaches to the same rare disease, joined forces to form a single entity focused on innovative kidney treatments.

Geographic Market Landscape Dominant Market Share: North America is expected to command the largest revenue share during the forecast period. This can be attributed to substantial advancements in the healthcare sector, a robust economic environment, and a focus on research and development by institutes to improve treatment technologies. Modern hospital infrastructures and the availability of experienced healthcare professionals further drive market growth. For instance, in March 2022, Lupin introduced Sevelamer Hydrochloride tablets (800 mg) for the treatment of hyperphosphatemia in chronic kidney disease patients, following approval from the USFDA.

Fastest Growing Region: The Asia Pacific region is projected to record a significant revenue CAGR in the forecast period. The presence of developing nations like India and China promotes healthcare industry expansion. The growing patient population in emerging countries is expected to drive demand for diagnostics and treatment methods, stimulating market revenue growth. Additionally, advanced therapeutic medications that focus on reducing calcium-phosphorus levels have emerged in recent years, contributing to rapid revenue growth in this region.

Key Market Trends and Innovations Kidney disease remains a global health concern, affecting over 10% of the world’s population and more than half of individuals over 70 in the United States. Clinical trials, such as the one conducted by the Veterans Medical Research Foundation in collaboration with the University of California and Genentech, Inc., for the prevention of Chronic Kidney Disease progression, have the potential to significantly impact the global revenue of the calciphylaxis treatment market.

Organic and Inorganic Strategies Adopted In February 2022, Opko Health, Inc. announced the commercial release of Rayaldee (extended-release calcifediol) in Germany by Vifor Fresenius Medical Care Renal Pharma. In November 2021, Vifor Pharma acquired Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company focusing on treatments for end-stage kidney disease patients with progressive vascular calcification disorders, and Inositec AG, a Swiss company developing first-in-class non-dialysis treatments for soft tissue and vascular calcification disorders. These acquisitions enable Vifor Pharma to address vascular calcification illnesses at various stages of chronic kidney diseases. In August 2021, AstraZeneca received European Union approval for Forxiga (dapagliflozin) for the treatment of Chronic Kidney Disease (CKD) in individuals with and without Type 2 Diabetes (T2D). In February 2020, Sanifit announced the successful dosing of the first patient in its pivotal phase 3 trial of SNF472, a treatment for calciphylaxis or Calcific Uremic Arteriolopathy (CUA).

Key Market Players The major companies in the market include:

• Amgen Inc.
• Vifor Pharma Management Ltd.
• AstraZeneca plc
• Opko Health Inc.
• Lupin
• Chinook Therapeutics Inc.
• Baxter
• GlaxoSmithKline plc
• Bayer AG
• Takeda Pharmaceutical Company Ltd.
• Pfizer Inc.
• Astellas Pharma Inc.
• Novartis AG
• Sanofi
• Merck and Co., Inc.

Market Segmentation The market is segmented by:

• Type (Uremic and Non-uremic)
• Treatment (Medication)
• Product (Tablets, Ointments, Creams, Intravenous Injections, and Others)
• Route of Administration (Oral, Parenteral, Topical)
• Distribution Channels (Online, Offline)
• End User (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Regional Segmentation The regional outlook includes:

• North America (U.S., Canada, Mexico)
• Europe (Germany, U.K., France, Italy, Spain, Benelux, Rest of Europe)
• Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
• Latin America (Brazil, Rest of Latin America)
• Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of MEA)

Report Overview This report provides historical data, forecasts, and revenue growth at global, regional, and country levels. It offers detailed analysis of industry trends and consumption patterns for each region, major country, and segment from 2019 to 2030. The report covers industry trends, drivers, restraints, opportunities, threats, market strategies, segment revenue, and revenue share by each regional and country market. Additionally, it provides industry analysis, a competitive landscape, company financials, and impact analysis.

Explore Trending Reports:

Epoxy Coating Market-https://www.globenewswire.com/news-release/2020/08/04/2072717/0/en/Epoxy-Coating-Market-To-Reach-USD-48-40-Billion-By-2027-Reports-and-Data.html

Membrane Separation Technology Market-https://www.globenewswire.com/news-release/2020/09/21/2096755/0/en/Membrane-Separation-Technology-Market-To-Reach-USD-43-14-Billion-By-2027-Reports-and-Data.html

Squalene Market-https://www.globenewswire.com/news-release/2019/04/24/1809010/0/en/Squalene-Market-To-Reach-USD-309-7-Million-By-2026-Reports-And-Data.html

Request a customization of the report: https://www.reportsanddata.com/request-customization-form/5873

Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.

About Reports and Data    

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: [email protected]

Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports

Browse More Latest Reports @ https://www.reportsanddata.com/report

Browse Latest Blogs: https://www.reportsanddata.com/blogs

Browse Latest Press Release: https://www.reportsanddata.com/press-release